Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies

References

• Romero R. Prenatal medicine: The child is the father of the man. Prenat Neonatal Med 1996; 1: 8–11
   Google Scholar
• Sibai B M, Gordon T, Thom E, Caritis S N, Klebanoff M, McNellis D, Paul R H. Risk factors for preeclampsia in healthy nulliparous women: A prospective multicenter study. Am J Obstet Gynecol 1995; 172: 642–648
   PubMed Web of Science ®Google Scholar
• Jacobsson B, Ladfors L, Milsom I. Advanced maternal age and adverse perinatal outcome. Obstet Gynecol 2004; 104: 727–733
   PubMed Web of Science ®Google Scholar
• Odibo A O, Nelson D, Stamilio D M, Sehdev H M, Macones G A. Advanced maternal age is an independent risk factor for intrauterine growth restriction. Am J Perinatol 2006; 23: 325–328
   PubMed Web of Science ®Google Scholar
• Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994; 171: 410–416
   PubMed Web of Science ®Google Scholar
• Goldenberg R L, Cliver S P. Small for gestational age and intrauterine growth restriction: Definitions and standards. Clin Obstet Gynecol 1997; 40: 704–714
   PubMed Web of Science ®Google Scholar
• Allen V M, Joseph K, Murphy K E, Magee L A, Ohlsson A. The effect of hypertensive disorders in pregnancy on small for gestational age and stillbirth: A population based study. BMC Pregnancy Childbirth 2004; 4: 17
   PubMedGoogle Scholar
• Zetterstrom K, Lindeberg S N, Haglund B, Hanson U. Chronic hypertension as a risk factor for offspring to be born small for gestational age. Acta Obstet Gynecol Scand 2006; 85: 1046–1050
   PubMed Web of Science ®Google Scholar
• Chao A S, Huang J Y, Lien R, Kung F T, Chen P J, Hsieh P C. Pregnancy in women who undergo long-term hemodialysis. Am J Obstet Gynecol 2002; 187: 152–156
   PubMedGoogle Scholar
• Ramin S M, Vidaeff A C, Yeomans E R, Gilstrap L C, III. Chronic renal disease in pregnancy. Obstet Gynecol 2006; 108: 1531–1539
   PubMed Web of Science ®Google Scholar
• Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 2006; 15: 148–155
   PubMed Web of Science ®Google Scholar
• Lin J, August P. Genetic thrombophilias and preeclampsia: A meta-analysis. Obstet Gynecol 2005; 105: 182–192
   PubMed Web of Science ®Google Scholar
• Brenner B. Thrombophilia and pregnancy complications. Pathophysiol Haemost Thromb 2006; 35: 28–35
   PubMedGoogle Scholar
• Weintraub A Y, Sheiner E, Levy A, Yerushalmi R, Mazor M. Pregnancy complications in women with inherited thrombophilia. Arch Gynecol Obstet 2006; 274: 125–129
   PubMedGoogle Scholar
• Carmona F, Font J, Cervera R, Munoz F, Cararach V, Balasch J. Obstetrical outcome of pregnancy in patients with systemic lupus erythematosus. A study of 60 cases. Eur J Obstet Gynecol Reprod Biol 1999; 83: 137–142
   PubMed Web of Science ®Google Scholar
• Moroni G, Quaglini S, Banfi G, Caloni M, Finazzi S, Ambroso G, Como G, Ponticelli C. Pregnancy in lupus nephritis. Am J Kidney Dis 2002; 40: 713–720
   PubMed Web of Science ®Google Scholar
• Brosens I A, Robertson W B, Dixon H G. The role of the spiral arteries in the pathogenesis of pre-eclampsia. J Pathol 1970; 101: vi
   Web of Science ®Google Scholar
• Brosens I A, Robertson W B, Dixon H G. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1: 177–191
   PubMedGoogle Scholar
• Brosens I, Dixon H G, Robertson W B. Fetal growth retardation and the arteries of the placental bed. Br J Obstet Gynaecol 1977; 84: 656–663
   PubMedGoogle Scholar
• De Wolf F, Brosens I, Renaer M. Fetal growth retardation and the maternal arterial supply of the human placenta in the absence of sustained hypertension. Br J Obstet Gynaecol 1980; 87: 678–685
   PubMedGoogle Scholar
• Khong T Y, De Wolf F, Robertson W B, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049–1059
   PubMedGoogle Scholar
• Pijnenborg R, Anthony J, Davey D A, Rees A, Tiltman A, Vercruysse L, van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98: 648–655
   PubMedGoogle Scholar
• Meekins J W, Pijnenborg R, Hanssens M, McFadyen I R, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669–674
   PubMedGoogle Scholar
• Brosens J J, Pijnenborg R, Brosens I A. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: A review of the literature. Am J Obstet Gynecol 2002; 187: 1416–1423
   PubMed Web of Science ®Google Scholar
• Robertson W B, Brosens I, Dixon G. Maternal uterine vascular lesions in the hypertensive complications of pregnancy. Perspect Nephrol Hypertens 1976; 5: 115–127
   PubMedGoogle Scholar
• Brosens I A. Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol 1977; 4: 573–593
   PubMed Web of Science ®Google Scholar
• Sheppard B L, Bonnar J. An ultrastructural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Br J Obstet Gynaecol 1981; 88: 695–705
   PubMedGoogle Scholar
• Campbell S, Diaz-Recasens J, Griffin D R, Cohen-Overbeek T E, Pearce J M, Willson K, Teague M J. New Doppler technique for assessing uteroplacental blood flow. Lancet 1983; 1: 675–677
   PubMed Web of Science ®Google Scholar
• Harrington K F, Campbell S, Bewley S, Bower S. Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. Eur J Obstet Gynecol Reprod Biol 1991; 42(Suppl)S14–S20
   PubMed Web of Science ®Google Scholar
• Bower S, Schuchter K, Campbell S. Doppler ultrasound screening as part of routine antenatal scanning: Prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1993; 100: 989–994
   PubMedGoogle Scholar
• Harrington K, Cooper D, Lees C, Hecher K, Campbell S. Doppler ultrasound of the uterine arteries: The importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol 1996; 7: 182–188
   PubMed Web of Science ®Google Scholar
• Conrad K P, Benyo D F. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997; 37: 240–249
   PubMed Web of Science ®Google Scholar
• Dekker G A, Sibai B M. Etiology and pathogenesis of preeclampsia: Current concepts. Am J Obstet Gynecol 1998; 179: 1359–1375
   PubMed Web of Science ®Google Scholar
• Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides K H. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2000; 96: 559–564
   PubMed Web of Science ®Google Scholar
• Papageorghiou A T, Yu C K, Bindra R, Pandis G, Nicolaides K H. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 441–449
   PubMed Web of Science ®Google Scholar
• Granger J P, Alexander B T, Llinas M T, Bennett W A, Khalil R A. Pathophysiology of preeclampsia: Linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 2002; 9: 147–160
   PubMed Web of Science ®Google Scholar
• Myatt L. Role of placenta in preeclampsia. Endocrine 2002; 19: 103–111
   PubMed Web of Science ®Google Scholar
• Kadyrov M, Schmitz C, Black S, Kaufmann P, Huppertz B. Pre-eclampsia and maternal anaemia display reduced apoptosis and opposite invasive phenotypes of extravillous trophoblast. Placenta 2003; 24: 540–548
   PubMed Web of Science ®Google Scholar
• Papageorghiou A T, Yu C K, Nicolaides K H. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 383–396
   PubMed Web of Science ®Google Scholar
• Fisher S J. The placental problem: Linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2004; 2: 53
   PubMedGoogle Scholar
• Roberts J M, Taylor R N, Musci T J, Rodgers G M, Hubel C A, McLaughlin M K. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200–1204
   PubMed Web of Science ®Google Scholar
• Clark B A, Halvorson L, Sachs B, Epstein F H. Plasma endothelin levels in preeclampsia: Elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol 1992; 166: 962–968
   PubMed Web of Science ®Google Scholar
• Taylor R N, de Groot C J, Cho Y K, Lim K H. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 17–31
   PubMedGoogle Scholar
• Roberts J M. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 5–15
   PubMedGoogle Scholar
• Poston L, Chappell L C. Is oxidative stress involved in the aetiology of pre-eclampsia?. Acta Paediatr Suppl 2001; 90: 3–5
   PubMedGoogle Scholar
• Bretelle F, Sabatier F, Blann A, D'Ercole C, Boutiere B, Mutin M, Boubli L, Sampol J, Dignat-George F. Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: Comparison with pre-eclampsia. BJOG 2001; 108: 1277–1282
   PubMed Web of Science ®Google Scholar
• Roberts J M, Lain K Y. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002; 23: 359–372
   PubMed Web of Science ®Google Scholar
• Johnson M R, Anim-Nyame N, Johnson P, Sooranna S R, Steer P J. Does endothelial cell activation occur with intrauterine growth restriction?. BJOG 2002; 109: 836–839
   PubMed Web of Science ®Google Scholar
• Redman C W, Sargent I L. Latest advances in understanding preeclampsia. Science 2005; 308: 1592–1594
   PubMed Web of Science ®Google Scholar
• Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez J B, Samoto T, Maruo T. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002; 186: 158–166
   PubMed Web of Science ®Google Scholar
• Kupferminc M J, Daniel Y, Englender T, Baram A, Many A, Jaffa A J, Gull I, Lessing J B. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 1997; 38: 302–306
   PubMed Web of Science ®Google Scholar
• Lyall F, Greer I A, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1997; 104: 223–228
   PubMedGoogle Scholar
• Torry D S, Wang H S, Wang T H, Caudle M R, Torry R J. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179: 1539–1544
   PubMed Web of Science ®Google Scholar
• Tidwell S C, Ho H N, Chiu W H, Torry R J, Torry D S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267–1272
   PubMed Web of Science ®Google Scholar
• Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher S J. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405–1423
   PubMed Web of Science ®Google Scholar
• Maynard S E, Min J Y, Merchan J, Lim K H, Li J, Mondal S, Libermann T A, Morgan J P, Sellke F W, Stillman I E, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348–2351
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, Brichant J F, Pignon M R, Noel A, Schaaps J P, Cabrol D, Frankenne F, Foidart J M. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555–5563
   PubMed Web of Science ®Google Scholar
• Krauss T, Pauer H U, Augustin H G. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101–111
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee K Y, Goncalves L F, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190: 1541–1547
   PubMed Web of Science ®Google Scholar
• Levine R J, Maynard S E, Qian C, Lim K H, England L J, Yu K F, Schisterman E F, Thadhani R, Sachs B P, Epstein F H, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683
   PubMed Web of Science ®Google Scholar
• McKeeman G C, Ardill J E, Caldwell C M, Hunter A J, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240–1246
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter W P, Wolf M, Levine R J, Taylor R N, Sukhatme V P, Ecker J, Karumanchi S A. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770–775
   PubMed Web of Science ®Google Scholar
• Rajakumar A, Michael H M, Rajakumar P A, Shibata E, Hubel C A, Karumanchi S A, Thadhani R, Wolf M, Harger G, Markovic N. Extra-placental expression of vascular endothelial growth factor receptor-1 (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005; 26: 563–573
   PubMed Web of Science ®Google Scholar
• Maynard S E, Venkatesha S, Thadhani R, Karumanchi S A. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005; 57: 1R–7R
   PubMed Web of Science ®Google Scholar
• Levine R J, Thadhani R, Qian C, Lam C, Lim K H, Yu K F, Blink A L, Sachs B P, Epstein F H, Sibai B M, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293: 77–85
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers R W, Larkin R W, Gilmour C, Bodnar L M, Crombleholme W R, Ness R B, Roberts J M, Hubel C A. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: Relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895–4903
   PubMed Web of Science ®Google Scholar
• Staff A C, Braekke K, Harsem N K, Lyberg T, Holthe M R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122: 33–39
   PubMed Web of Science ®Google Scholar
• Levine R J, Karumanchi S A. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005; 48: 372–386
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim Y M, Kim G J, Kim M R, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3–18
   PubMed Web of Science ®Google Scholar
• Malamitsi-Puchner A, Boutsikou T, Economou E, Sarandakou A, Makrakis E, Hassiakos D, Creatsas G. Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm 2005; 2005: 293–297
   PubMed Web of Science ®Google Scholar
• Espinoza J, Romero R, Nien J K, Kusanovic J P, Richani K, Gomez R, Kim C J, Mittal P, Gotsh F, Erez O, et al. A role of the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome’ (Ballantyne's syndrome). J Matern Fetal Neonatal Med 2006; 19: 607–613
   PubMed Web of Science ®Google Scholar
• Aggarwal P K, Jain V, Sakhuja V, Karumanchi S A, Jha V. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 2006; 69: 621–624
   PubMed Web of Science ®Google Scholar
• Levine R J, Lam C, Qian C, Yu K F, Maynard S E, Sachs B P, Sibai B M, Epstein F H, Romero R, Thadhani R, et al. Soluble endoglin and other circulating anti-angiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992–1005
   PubMed Web of Science ®Google Scholar
• Stepan H, Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 2006; 354: 1857–1858
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y M, Bdolah Y, Lim K H, Yuan H T, Libermann T A, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–649
   PubMed Web of Science ®Google Scholar
• Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201–207
   PubMed Web of Science ®Google Scholar
• Espinoza J, Nien J K, Kusanovic J P, Goncalves L F, Medina L H, Gomez R, Romero R. The combined use of uterine artery Doppler and maternal plasma placental growth factor concentrations identifies patients at risk for early onset and/or severe preeclampsia. Ultrasound Obstet Gynecol 2006; 28: 387–388
   Google Scholar
• Robinson C J, Johnson D D, Chang E Y, Armstrong D M, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195: 255–259
   PubMed Web of Science ®Google Scholar
• Boutsikou T, Malamitsi-Puchner A, Economou E, Boutsikou M, Puchner K P, Hassiakos D. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 2006; 82: 235–239
   PubMed Web of Science ®Google Scholar
• Girardi G, Yarilin D, Thurman J M, Holers V M, Salmon J E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203: 2165–2175
   PubMed Web of Science ®Google Scholar
• Padavala S, Pope N, Baker P, Crocker I. An imbalance between vascular endothelial growth factor and its soluble receptor in placental villous explants of intrauterine growth-restricted pregnancies. J Soc Gynecol Investig 2006; 13: 40–47
   PubMedGoogle Scholar
• Wallner W, Sengenberger R, Strick R, Strissel P L, Meurer B, Beckmann M W, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112: 51–57
   PubMed Web of Science ®Google Scholar
• Sacks G P, Studena K, Sargent K, Redman C W. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998; 179: 80–86
   PubMed Web of Science ®Google Scholar
• Redman C W, Sacks G P, Sargent I L. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499–506
   PubMed Web of Science ®Google Scholar
• Redman C W, Sargent I L. Placental debris, oxidative stress and pre-eclampsia. Placenta 2000; 21: 597–602
   PubMed Web of Science ®Google Scholar
• Redman C W, Sargent I L. The pathogenesis of pre-eclampsia. Gynecol Obstet Fertil 2001; 29: 518–522
   PubMedGoogle Scholar
• Gervasi M T, Chaiworapongsa T, Pacora P, Naccasha N, Yoon B H, Maymon E, Romero R. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001; 185: 792–797
   PubMed Web of Science ®Google Scholar
• Bartha J L, Romero-Carmona R, Comino-Delgado R. Inflammatory cytokines in intrauterine growth retardation. Acta Obstet Gynecol Scand 2003; 82: 1099–1102
   PubMed Web of Science ®Google Scholar
• Hahn-Zoric M, Hagberg H, Kjellmer I, Ellis J, Wennergren M, Hanson L A. Aberrations in placental cytokine mRNA related to intrauterine growth retardation. Pediatr Res 2002; 51: 201–206
   PubMed Web of Science ®Google Scholar
• Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol 2003; 59: 161–173
   PubMed Web of Science ®Google Scholar
• Sunder-Plassmann G, Derfler K, Wagner L, Stockenhuber F, Endler M, Nowotny C, Balcke P. Increased serum activity of interleukin-2 in patients with pre-eclampsia. J Autoimmun 1989; 2: 203–205
   PubMed Web of Science ®Google Scholar
• Meekins J W, McLaughlin P J, West D C, McFadyen I R, Johnson P M. Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin Exp Immunol 1994; 98: 110–114
   PubMed Web of Science ®Google Scholar
• Kupferminc M J, Peaceman A M, Wigton T R, Rehnberg K A, Socol M L. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994; 170: 1752–1757
   PubMed Web of Science ®Google Scholar
• Vince G S, Starkey P M, Austgulen R, Kwiatkowski D, Redman C W. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995; 102: 20–25
   PubMedGoogle Scholar
• Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J. T helper 1- and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1999; 86: 165–170
   PubMed Web of Science ®Google Scholar
• Saito S, Umekage H, Sakamoto Y, Sakai M, Tanebe K, Sasaki Y, Morikawa H. Increased T-helper-1-type immunity and decreased T-helper-2-type immunity in patients with preeclampsia. Am J Reprod Immunol 1999; 41: 297–306
   PubMed Web of Science ®Google Scholar
• Ida A, Tsuji Y, Muranaka J, Kanazawa R, Nakata Y, Adachi S, Okamura H, Koyama K. IL-18 in pregnancy; the elevation of IL-18 in maternal peripheral blood during labour and complicated pregnancies. J Reprod Immunol 2000; 47: 65–74
   PubMed Web of Science ®Google Scholar
• Rein D T, Schondorf T, Gohring U J, Kurbacher C M, Pinto I, Breidenbach M, Mallmann P, Kolhagen H, Engel H. Cytokine expression in peripheral blood lymphocytes indicates a switch to T(HELPER) cells in patients with preeclampsia. J Reprod Immunol 2002; 54: 133–142
   PubMed Web of Science ®Google Scholar
• Darmochwal-Kolarz D, Rolinski J, Leszczynska-Goarzelak B, Oleszczuk J. The expressions of intracellular cytokines in the lymphocytes of preeclamptic patients. Am J Reprod Immunol 2002; 48: 381–386
   PubMed Web of Science ®Google Scholar
• Sakai M, Tsuda H, Tanebe K, Sasaki Y, Saito S. Interleukin-12 secretion by peripheral blood mononuclear cells is decreased in normal pregnant subjects and increased in preeclamptic patients. Am J Reprod Immunol 2002; 47: 91–97
   PubMed Web of Science ®Google Scholar
• Sakai M, Shiozaki A, Sasaki Y, Yoneda S, Saito S. The ratio of interleukin (IL)-18 to IL-12 secreted by peripheral blood mononuclear cells is increased in normal pregnant subjects and decreased in pre-eclamptic patients. J Reprod Immunol 2004; 61: 133–143
   PubMed Web of Science ®Google Scholar
• Jonsson Y, Matthiesen L, Berg G, Ernerudh J, Nieminen K, Ekerfelt C. Indications of an altered immune balance in preeclampsia: A decrease in in vitro secretion of IL-5 and IL-10 from blood mononuclear cells and in blood basophil counts compared with normal pregnancy. J Reprod Immunol 2005; 66: 69–84
   PubMed Web of Science ®Google Scholar
• Marzi M, Vigano A, Trabattoni D, Villa M L, Salvaggio A, Clerici E, Clerici M. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996; 106: 127–133
   PubMed Web of Science ®Google Scholar
• Omu A E, Makhseed M, al-Qattan F. The comparative value of interleukin-4 in sera of women with preeclampsia and cord sera. Nutrition 1995; 11: 688–691
   PubMed Web of Science ®Google Scholar
• Omu A E, al-Qattan F, Diejomaoh M E, Al-Yatama M. Differential levels of T helper cytokines in preeclampsia: Pregnancy, labor and puerperium. Acta Obstet Gynecol Scand 1999; 78: 675–680
   PubMed Web of Science ®Google Scholar
• Engel S A, Olshan A F, Savitz D A, Thorp J, Erichsen H C, Chanock S J. Risk of small-for-gestational age is associated with common anti-inflammatory cytokine polymorphisms. Epidemiology 2005; 16: 478–486
   PubMed Web of Science ®Google Scholar
• Smith C A, Davis T, Anderson D, Solam L, Beckmann M P, Jerzy R, Dower S K, Cosman D, Goodwin R G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019–1023
   PubMed Web of Science ®Google Scholar
• Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421–427
   PubMed Web of Science ®Google Scholar
• Smith C A, Gruss H J, Davis T, Anderson D, Farrah T, Baker E, Sutherland G R, Brannan C I, Copeland N G, Jenkins N A, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73: 1349–1360
   PubMed Web of Science ®Google Scholar
• Del Prete G, De Carli M, Almerigogna F, Daniel C K, D'Elios M M, Zancuoghi G, Vinante F, Pizzolo G, Romagnani S. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995; 9: 81–86
   PubMed Web of Science ®Google Scholar
• Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995; 57: 726–730
   PubMed Web of Science ®Google Scholar
• Gruss H J, Boiani N, Williams D E, Armitage R J, Smith C A, Goodwin R G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045–2056
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli M F, Stein H. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1–14
   PubMed Web of Science ®Google Scholar
• Lee S Y, Park C G, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996; 183: 669–674
   PubMed Web of Science ®Google Scholar
• Hansen H P, Kisseleva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 1995; 63: 750–756
   PubMed Web of Science ®Google Scholar
• Hansen H P, Dietrich S, Kisseleva T, Mokros T, Mentlein R, Lange H H, Murphy G, Lemke H. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol 2000; 165: 6703–6709
   PubMed Web of Science ®Google Scholar
• Alexander G R, Himes J H, Kaufman R B, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996; 87: 163–168
   PubMed Web of Science ®Google Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–S22
   PubMed Web of Science ®Google Scholar
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 159–167
   PubMed Web of Science ®Google Scholar
• Sibai B M, Ewell M, Levine R J, Klebanoff M A, Esterlitz J, Catalano P M, Goldenberg R L, Joffe G. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) study group. Am J Obstet Gynecol 1997; 177: 1003–1010
   PubMed Web of Science ®Google Scholar
• Froese P, Lemke H, Gerdes J, Havsteen B, Schwarting R, Hansen H, Stein H. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol 1987; 139: 2081–2087
   PubMed Web of Science ®Google Scholar
• Nawrocki J F, Kirsten E S, Fisher R I. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol 1988; 141: 672–680
   PubMed Web of Science ®Google Scholar
• Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299: 65–67
   PubMed Web of Science ®Google Scholar
• Stein H, Mason D Y, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed–Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–858
   PubMed Web of Science ®Google Scholar
• Smith C A, Farrah T, Goodwin R G. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994; 76: 959–962
   PubMed Web of Science ®Google Scholar
• Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989; 19: 157–162
   PubMed Web of Science ®Google Scholar
• Fonatsch C, Latza U, Durkop H, Rieder H, Stein H. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 1992; 14: 825–826
   PubMed Web of Science ®Google Scholar
• Kim K H, Oh E J, Jung E S, Park Y J, Choi J Y, Kim D G, Lee K Y, Kang C S. Evaluation of pre- and post-transplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection. Transplant Proc 2006; 38: 1429–1431
   Google Scholar
• Ayed K, Abdallah T B, Bardi R, Abderrahim E, Kheder A. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection. Transplant Proc 2006; 38: 2300–2302
   Google Scholar
• Dong W, Shunliang Y, Weizhen W, Qinghua W, Zhangxin Z, Jianming T, He W. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 2006; 16: 41–45
   Google Scholar
• Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B. Identification of patients at risk of acute rejection by pretransplantation and post-transplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 2006; 81: 1216–1219
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Vinante F, Chilosi M, Dallenbach F, Josimovic-Alasevic O, Diamantstein T, Stein H. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: Relationship with disease activity and clinical stage. Br J Haematol 1990; 75: 282–284
   PubMed Web of Science ®Google Scholar
• Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti M M, Benedetti F, Vassanelli A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12: 793–797
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandini G, Sinicco A, Raiteri R, Semenzato G, Stein H, et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 1994; 8: 741–745
   PubMed Web of Science ®Google Scholar
• Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L, Chilosi M, Menestrina F, Kinney M C, Greer J P, et al. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol 1995; 13: 1355–1360
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Bertero M T, Converso M, Stacchini A, Vinante F, Romagnani S, Pizzolo G. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995; 13: 339–343
   PubMed Web of Science ®Google Scholar
• Wang G, Hansen H, Tatsis E, Csernok E, Lemke H, Gross W L. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997; 102: 517–523
   PubMed Web of Science ®Google Scholar
• Okumura M, Hidaka Y, Kuroda S, Takeoka K, Tada H, Amino N. Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1997; 82: 1757–1760
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Vinante F, Nadali G, Krampera M, Morosato L, Chilosi M, Raiteri R, Sinicco A. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997; 108: 251–253
   PubMed Web of Science ®Google Scholar
• Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo, N, Carotenuto M, Chilosi M, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998; 91: 3011–3016
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Pileri S, Bendandi M, Buzzi M, Sabattini E, Ascani S, Gherlinzoni F, Magagnoli M, Albertini P, Tura S. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 1998; 16: 1532–1537
   PubMed Web of Science ®Google Scholar
• Kadin M E. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 2000; 156: 1479–1484
   PubMed Web of Science ®Google Scholar
• Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. BER-H2: A new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989; 74: 1678–1689
   PubMed Web of Science ®Google Scholar
• Ito K, Watanabe T, Horie R, Shiota M, Kawamura S, Mori S. High expression of the CD30 molecule in human decidual cells. Am J Pathol 1994; 145: 276–280
   PubMed Web of Science ®Google Scholar
• Agrawal B, Reddish M, Longenecker B M. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996; 157: 3229–3234
   PubMed Web of Science ®Google Scholar
• Ellis T M, Simms P E, Slivnick D J, Jack H M, Fisher R I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993; 151: 2380–2389
   PubMed Web of Science ®Google Scholar
• Romagnani P, Annunziato F, Manetti R, Mavilia C, Lasagni L, Manuelli C, Vannelli G B, Vanini V, Maggi E, Pupilli C, et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 1998; 91: 3323–3332
   PubMed Web of Science ®Google Scholar
• Horie R, Watanabe T. CD30: Expression and function in health and disease. Semin Immunol 1998; 10: 457–470
   PubMed Web of Science ®Google Scholar
• Manetti R, Annunziato F, Biagiotti R, Giudizi M G, Piccinni M P, Giannarini L, Sampognaro S, Parronchi P, Vinante F, Pizzolo G, et al. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8 + CD30+ T cell clones in human immunodeficiency virus infection. J Exp Med 1994; 180: 2407–2411
   PubMed Web of Science ®Google Scholar
• Fattovich G, Vinante F, Giustina G, Morosato L, Alberti A, Ruol A, Pizzolo G. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996; 103: 105–110
   PubMed Web of Science ®Google Scholar
• Vinante F, Krampera M, Morosato L, Rigo A, Romagnani S, Pizzolo G. Peripheral T lymphocyte cytokine profile (IFN-gamma, IL-2, IL-4) and CD30 expression/release during measles infection. Haematologica 1999; 84: 683–689
   PubMed Web of Science ®Google Scholar
• Mavalia C, Scaletti C, Romagnani P, Carossino A M, Pignone A, Emmi L, Pupilli C, Pizzolo G, Maggi E, Romagnani S. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997; 151: 1751–1758
   PubMed Web of Science ®Google Scholar
• D'Elios M M, Romagnani P, Scaletti C, Annunziato F, Manghetti M, Mavilia C, Parronchi P, Pupilli C, Pizzolo G, Maggi E, et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 1997; 61: 539–544
   PubMed Web of Science ®Google Scholar
• Chilosi M, Facchetti F, Notarangelo L D, Romagnani S, Del Prete G, Almerigogna F, De Carli M, Pizzolo G. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: Evidence for a T helper 2-mediated condition. Eur J Immunol 1996; 26: 329–334
   PubMed Web of Science ®Google Scholar
• Barner M, Kopf M, Lefrang K. CD30 is a specific marker for Th2 cells but is not required for their development. Basil institute for immunology 1997; 62: 54, Annual Report
   Google Scholar
• Bengtsson A, Johansson C, Linder M T, Hallden G, van der Ploeg I, Scheynius A. Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. J Leukoc Biol 1995; 58: 683–689
   PubMed Web of Science ®Google Scholar
• Hamann D, Hilkens C M, Grogan J L, Lens S M, Kapsenberg M L, Yazdanbakhsh M, van Lier R A. CD30 expression does not discriminate between human Th1- and Th2-type T cells. J Immunol 1996; 156: 1387–1391
   PubMed Web of Science ®Google Scholar
• Pellegrini P, Berghella A M, Contasta I, Adorno D. CD30 antigen: Not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003; 12: 49–61
   PubMed Web of Science ®Google Scholar
• Wegmann T G, Lin H, Guilbert L, Mosmann T R. Bidirectional cytokine interactions in the maternal–fetal relationship: Is successful pregnancy a TH2 phenomenon?. Immunol Today 1993; 14: 353–356
   PubMedGoogle Scholar
• Hoshimoto K, Ohta N, Ohkura T, Inaba N. Changes in plasma soluble CD26 and CD30 during pregnancy: Markers of Th1/Th2 balance?. Gynecol Obstet Invest 2000; 50: 260–263
   PubMed Web of Science ®Google Scholar
• Ostensen M, Forger F, Nelson J L, Schuhmacher A, Hebisch G, Villiger P M. Pregnancy in patients with rheumatic disease: Anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis 2005; 64: 839–844
   PubMed Web of Science ®Google Scholar
• Ekstrom E S, Bengtsson A, Svensson A, Nilsson C, Ostlund E, Sandstedt B, Bremme K, Lilja G, Scheynius A. Presence of CD30(+) and CD30L(+) cells in human placenta and soluble CD30 levels in cord blood are independent of maternal atopy. Placenta 2001; 22: 372–379
   PubMed Web of Science ®Google Scholar
• Lin H, Mosmann T R, Guilbert L, Tuntipopipat S, Wegmann T G. Synthesis of T helper 2-type cytokines at the maternal–fetal interface. J Immunol 1993; 151: 4562–4573
   PubMed Web of Science ®Google Scholar
• Roth I, Corry D B, Locksley R M, Abrams J S, Litton M J, Fisher S J. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J Exp Med 1996; 184: 539–548
   PubMed Web of Science ®Google Scholar
• Dudley D J, Chen C L, Mitchell M D, Daynes R A, Araneo B A. Adaptive immune responses during murine pregnancy: Pregnancy-induced regulation of lymphokine production by activated T lymphocytes. Am J Obstet Gynecol 1993; 168: 1155–1163
   PubMed Web of Science ®Google Scholar
• Hanna N, Hanna I, Hleb M, Wagner E, Dougherty J, Balkundi D, Padbury J, Sharma S. Gestational age-dependent expression of IL-10 and its receptor in human placental tissues and isolated cytotrophoblasts. J Immunol 2000; 164: 5721–5728
   PubMed Web of Science ®Google Scholar
• Chaouat G, Assal Meliani A, Martal J, Raghupathy R, Elliott J F, Mosmann T, Wegmann T G. IL-10 prevents naturally occurring fetal loss in the CBA×DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J Immunol 1995; 154: 4261–4268
   PubMed Web of Science ®Google Scholar
• Hill J A, Polgar K, Anderson D J. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA 1995; 273: 1933–1936
   PubMed Web of Science ®Google Scholar
• Piccinni M P, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med 1998; 4: 1020–1024
   PubMed Web of Science ®Google Scholar
• Makhseed M, Raghupathy R, Azizieh F, Al-Azemi M M, Hassan N A, Bandar A. Mitogen-induced cytokine responses of maternal peripheral blood lymphocytes indicate a differential Th-type bias in normal pregnancy and pregnancy failure. Am J Reprod Immunol 1999; 42: 273–281
   PubMed Web of Science ®Google Scholar
• Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, Farhat R. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod 2000; 15: 713–718
   PubMed Web of Science ®Google Scholar
• Makhseed M, Raghupathy R, Azizieh F, Omu A, Al-Shamali E, Ashkanani L. Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Hum Reprod 2001; 16: 2219–2226
   PubMed Web of Science ®Google Scholar
• Ng S C, Gilman-Sachs A, Thaker P, Beaman K D, Beer A E, Kwak-Kim J. Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. Am J Reprod Immunol 2002; 48: 77–86
   PubMed Web of Science ®Google Scholar
• Ostensen M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand J Rheumatol 1983; 12: 69–72
   PubMed Web of Science ®Google Scholar
• Al-Shammri S, Rawoot P, Azizieh F, AbuQoora A, Hanna M, Saminathan T R, Raghupathy R. Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis. J Neurol Sci 2004; 222: 21–27
   PubMed Web of Science ®Google Scholar
• Meekins J W, McLaughlin P J, West D C, McFadyen I R, Johnson P M. Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin Exp Immunol 1994; 98: 110–114
   PubMed Web of Science ®Google Scholar
• Conrad K P, Miles T M, Benyo D F. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998; 40: 102–111
   PubMed Web of Science ®Google Scholar
• Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet 2001; 75: 243–249
   PubMed Web of Science ®Google Scholar
• Benyo D F, Smarason A, Redman C W, Sims C, Conrad K P. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001; 86: 2505–2512
   PubMed Web of Science ®Google Scholar
• Arriaga-Pizano L, Jimenez-Zamudio L, Vadillo-Ortega F, Martinez-Flores A, Herrerias-Canedo T, Hernandez-Guerrero C. The predominant Th1 cytokine profile in maternal plasma of preeclamptic women is not reflected in the choriodecidual and fetal compartments. J Soc Gynecol Investig 2005; 12: 335–342
   PubMedGoogle Scholar
• Hennessy A, Pilmore H L, Simmons L A, Painter D M. A deficiency of placental IL-10 in preeclampsia. J Immunol 1999; 163: 3491–3495
   PubMed Web of Science ®Google Scholar
• Adams K M, Mandel L S, Guthrie K A, Atkinson M W. Interleukin-18 in the plasma of women with preeclampsia. Am J Obstet Gynecol 2003; 188: 1234–1237
   Google Scholar
• Rinehart B K, Terrone D A, Lagoo-Deenadayalan S, Barber W H, Hale E A, Martin J N, Jr, Bennett W A. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 1999; 181: 915–920
   PubMed Web of Science ®Google Scholar
• Wang Y, Walsh S W. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 1996; 32: 157–169
   PubMed Web of Science ®Google Scholar
• Heinig J, Wilhelm S, Muller H, Briese V, Bittorf T, Brock J. Determination of cytokine mRNA-expression in term human placenta of patients with gestational hypertension, intrauterine growth retardation and gestational diabetes mellitus using polymerase chain reaction. Zentralbl Gynakol 2000; 122: 413–418
   PubMedGoogle Scholar
• Holcberg G, Huleihel M, Sapir O, Katz M, Tsadkin M, Furman B, Mazor M, Myatt L. Increased production of tumor necrosis factor-alpha TNF-alpha by IUGR human placentae. Eur J Obstet Gynecol Reprod Biol 2001; 94: 69–72
   PubMed Web of Science ®Google Scholar